Amgen stock holds above $415 as Q2 2026 growth and guidance support valuation

Amgen Inc. (ISIN US0311621009) stock traded at $419.38 at the Nasdaq close on August 17, 2026, placing the shares within dollars of their recent 52-week high after a strong second quarter and higher full-year earnings outlook underpinned sentiment. Per recent market data, the stock also changed hands at $421.81 in post-market trading on the same date, highlighting sustained investor interest into the evening session.

Q2 2026 results beat forecasts

Recent earnings commentary indicates that Amgen generated second-quarter 2026 revenue of $10.1 billion, representing a 10 percent increase year over year and marking one of the company’s strongest quarterly top-line expansions in recent years. A detailed overview of the quarter notes that management reported second quarter 2026 revenues of $10.1 billion, with six key growth drivers collectively expanding sales by 26 percent year over year and contributing nearly 70 percent of product revenue for the period. The same review highlights that the company’s GAAP earnings per share for Q2 2026 rose 65 percent to $4.37, while non-GAAP EPS increased 4 percent to $6.29 compared with the prior-year quarter.

Additional analyst-focused summaries of the quarter point out that Amgen’s reported second-quarter revenue of $10.05 billion exceeded consensus expectations of $9.43 billion, implying a revenue beat of $0.62 billion. In the same context, non-GAAP EPS of $6.29 per share came in $0.67 above an analyst consensus estimate of $5.62, providing a concrete indication that profitability outperformed market forecasts despite continued investment in the company’s late-stage pipeline. Commentary on the period also underlines that, versus the $6.02 per-share result reported in the comparable quarter a year earlier, the latest non-GAAP EPS figure represents growth in earnings of 4.5 percent on this adjusted basis even as GAAP profitability saw a much steeper improvement.

The step-up in earnings and revenue is further reflected in Amgen’s cash generation. A Q2-focused summary notes that the company produced $3.5 billion in free cash flow in the second quarter of 2026, up from $1.9 billion in the same quarter of the prior year, which indicates an increase of $1.6 billion and demonstrates that stronger operating performance is translating into more cash available for dividends, debt reduction, and business development. That cash-flow expansion supports management’s ability to fund a broad portfolio of therapies while maintaining shareholder returns.

Guidance raised and dividend supports returns

Current fiscal-year commentary indicates that Amgen has set its guidance for full-year 2026 non-GAAP earnings per share in a range of $22.30 to $23.50. This range reflects an upward revision versus previous expectations and embeds the impact of the stronger-than-expected performance in the second quarter. Analyst roundups of this guidance suggest that, based on current projections, Wall Street expects the company to deliver full-year 2026 EPS of around $22.78, roughly at the midpoint of management’s range and signifying continued confidence that the business can sustain double-digit earnings power.

Alongside its earnings outlook, Amgen’s capital-return profile continues to play a central role in the investment case. Recent dividend-focused analyses state that the company’s board has declared a quarterly dividend of $2.52 per share. On an annualized basis, this equates to a payout of $10.08 per share and implies a dividend yield of 2.4 percent when measured against recent trading levels. For income-sensitive investors, that yield represents a meaningful cash return, particularly when paired with the company’s history of regular dividend growth and the improved free cash flow cushion observed in the second quarter of 2026.

Analyst consensus on the stock remains measured despite the recent operational outperformance. Summaries of current recommendations describe the overall rating on the shares as a Hold, with an average published price target of $372.39. When compared with the recent share price of roughly $415.21 cited in multiple market overviews, this average target sits more than $40 below the latest quote, suggesting that, on average, analysts see limited upside from current levels even though some individual targets likely sit above the mean. That gap between price and consensus target is one reason valuation has become a more prominent topic in recent discussions of the name.

Shares trade close to 52-week high

Market data snapshots for August 17, 2026 show Amgen stock closing at $415.21 in regular trading, with the shares moving in a daily range from $410.50 to $415.38 on that session. At the same time, the company’s market capitalization stood at $224.6 billion based on that closing price, underscoring its status as one of the largest global biopharmaceutical companies. Over the last year, the stock has traded in a 52-week range between $269.77 and $421.79, placing the latest closing level much closer to the top than the bottom of that band and highlighting the strength of the recent rally.

Technical-oriented commentary notes that, at $415.21 as of August 17, 2026, Amgen’s stock price stood significantly above both its 50-day and 200-day moving averages, which were cited at $370.57 and $358.99 respectively in the same data set. That means the shares were trading $44.64 above the 50-day moving average and $56.22 above the 200-day measure at that time, indicating a sustained uptrend rather than a short-lived spike. For investors who track such indicators, a price so far above these moving averages often confirms positive momentum but may also raise questions about whether the stock is extended in the short term.

Additional quote services present a similar picture using end-of-day values for August 17, 2026. One real-time pricing feed shows Amgen stock at $419.38 at 3:59:59 p.m. ET, marking a gain of 1.00 percent versus the prior close, with the subsequent post-market indication at $418.88 by 7:59 p.m. ET. Another service lists the company’s stock changing hands at $419.22, representing a daily advance of 0.97 percent at the close, again underscoring modest but steady gains. Across these differing quote snapshots, the common thread is that the shares are consolidating only a few dollars below the 52-week high threshold, which makes any new catalyst, positive or negative, potentially more impactful on short-term trading.

Pipeline and product drivers

Behind the headline numbers, the primary engine of Amgen’s recent growth remains its portfolio of innovative and biosimilar therapies across oncology, inflammation, cardiovascular disease, bone health, and other serious conditions. The Q2 2026 commentary that attributes 26 percent year-over-year growth to six key growth drivers suggests that the company’s strategy of focusing on a concentrated group of high-potential products is paying off, as these medicines now account for nearly 70 percent of product sales. That concentration can enhance operating leverage when volumes rise, but it also means that the performance of a handful of drugs has a disproportionate influence on quarterly results.

In oncology, Amgen continues to invest in targeted therapies and immuno-oncology approaches that can be combined with existing standards of care. The company’s biologic treatments for certain hematologic malignancies and solid tumors remain core revenue contributors, and newer launches are gradually supplementing older blockbusters whose exclusivity periods are expiring. In cardiovascular disease, agents that address elevated cholesterol and other risk factors seek to tap large global patient populations, with pricing and reimbursement dynamics playing a key role in the ramp profiles. Autoimmune and inflammation franchises, including therapies for conditions such as rheumatoid arthritis and psoriasis, also contribute meaningfully to the top line and provide diversification across therapeutic areas.

Beyond its wholly owned drugs, Amgen has systematically built out a presence in biosimilars, leveraging its longstanding capabilities in biologics manufacturing to produce follow-on versions of established biologic therapies as originator patents expire. This business offers the opportunity to participate in large existing markets while exerting pricing pressure that can benefit healthcare systems and patients. Because biosimilar markets often feature multiple competitors, however, Amgen’s execution in fields such as oncology supportive care and autoimmune disorders must remain sharp to defend market share and margins. The second-quarter performance, with double-digit growth and strong free cash flow, indicates that the mix of innovative and biosimilar products is currently delivering both revenue expansion and cash generation.

Valuation, risks, and investor view

From a valuation standpoint, the combination of a recent share price north of $415, consensus 2026 EPS expectations of approximately $22.78, and a dividend of $10.08 per share annually frames how investors might assess the stock. Using these figures, the shares trade at a forward price-to-earnings multiple in the high-teens, with the dividend yield at 2.4 percent providing a tangible cash return on top of projected earnings growth. The fact that the average published price target of $372.39 sits below the current share price suggests that the market is already capitalizing a good portion of the expected earnings trajectory and pipeline value.

Key risks that investors typically consider include patent expirations on legacy products, competition from other large biopharmaceutical companies and emerging biotech firms, pricing pressure from payers and regulators, and execution risk around clinical trials and regulatory approvals. Should one of the company’s marquee clinical programs fail to meet its endpoints or face an unexpected delay in regulatory review, the impact on sentiment could be material, especially with the stock trading close to its 52-week high range. Conversely, positive trial results, label expansions, or favorable reimbursement decisions could reinforce the current valuation and potentially justify further gains from these elevated levels.

Overall, the latest data through August 17, 2026 depict a company with double-digit revenue growth, a meaningful EPS beat versus expectations in the latest reported quarter, robust free cash flow, and a shareholder-return profile that combines a 2.4 percent dividend yield with ongoing reinvestment in a diversified pipeline. With the shares priced close to their one-year high and trading well above key moving averages, investors will likely focus on the next set of quarterly results and pipeline milestones to determine whether recent momentum in Amgen stock can be sustained or whether the valuation begins to reflect most of the near-term good news.

Flagship therapies underpin the brand

Among Amgen’s many medicines, its flagship biologic therapies in oncology and autoimmune disease, together with newer cardiovascular and bone-health agents, remain emblematic of the company’s scientific and commercial profile. These products often command premium pricing, require sophisticated manufacturing, and rely on extensive clinical and real-world evidence to maintain physician and payer support. The strong second-quarter revenue performance, in which six key products delivered 26 percent year-over-year growth and accounted for nearly 70 percent of product sales, indicates that this flagship cluster continues to gain traction in both mature and newer indications.

For patients, the practical impact of Amgen’s portfolio is measured in improved clinical outcomes, extended survival, or enhanced quality of life, depending on the condition being treated. For investors, the same portfolio generates recurring revenue streams that support long-term cash flow and dividends, provided that the company continues to execute on lifecycle management, indication expansions, and competitive differentiation. The balance between protecting established franchises and advancing the next wave of therapies is central to how the market values Amgen today.

Amgen stock level and as-of date

As of the most recent completed trading session on August 17, 2026, Amgen stock closed at $419.38 on the Nasdaq, with post-market indications showing the shares trading modestly lower at $418.88 later that evening. In parallel, other quote snapshots for the same date cited a closing level of $415.21, a market capitalization of $224.6 billion, and a 52-week trading range stretching from $269.77 to $421.79, underscoring that even on small day-to-day moves the stock remains positioned close to the upper end of its one-year range. These figures frame the current equity-market view on Amgen as investors digest the Q2 2026 beat, raised full-year guidance, and ongoing dividend payments while looking ahead to the company’s next set of financial and clinical updates.

Read more

Amgen stock price history and recent trading ranges Ad-hoc analysis of Amgen stock after Q2 sales raised the bar Real-time Amgen stock quote snapshot

Fact box

Company: Amgen Inc.
ISIN: US0311621009
Ticker: AMGN
Exchange: Nasdaq
Price (as of August 17, 2026, 3:59 p.m. ET): $419.38 USD
Market cap: $224.6 billion (as of August 17, 2026)
Sector / Industry: Health care / Biotechnology
Index membership: S&P 500